Transcriptomics

Dataset Information

0

Immunogenic cell death inducer cEmsy boosted cancer immunotherapy in lung adenocarcinoma


ABSTRACT: Immunogenic cell death (ICD) represents a spectacular approach to boosting tumor immunotherapy by inducing an adaptive immune response, and it is urgent to identify effective and safe ICD inducers. Here, we identified a conserved, ICD-related circular RNA-cEmsy/cEMSY by performing a systematic screening utilizing immunogenic cell death models induced by multiple cell stressors in lung adenocarcinoma (LUAD). cEmsy/cEMSY triggers ICD in LUAD both in vitro and in vivo, leading to the release of damage-associated molecular patterns (DAMPs) and promoting T-cell cross-priming by dendritic cells (DCs). Notably, in the immunosuppressive tumor model, intratumoral delivery of in vitro-transcribed cEmsy encapsulated in lipid nanoparticles (LNP) induces a potent anti-tumor immune response, which synergizes with PD-1 blockade to facilitate long-term cancer immunity with no apparent toxicities. Mechanistically, cEmsy/cEMSY facilitates TDP-43 aggregation in mitochondria and leverages mitochondrial DNA leakage, activating the cGAS-STING pathway and initiating an antiviral immune response. Clinically, elevated expression level of cEMSY correlates with enhanced DCs and CD8+ T cell infiltration, and favorable immunotherapy response in LUAD. Hence, cEmsy/cEMSY emerges as a safe and potent ICD inducer, offering a dual advantage as a mechanism-based target and a biomarker for enhancing ICI responses in LUAD treatment.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE266364 | GEO | 2024/10/30

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-05-23 | PXD043560 | Pride
2019-02-25 | GSE126988 | GEO
2022-08-08 | E-MTAB-11799 | biostudies-arrayexpress
2024-09-30 | GSE270711 | GEO
2024-12-11 | GSE283933 | GEO
2024-10-01 | GSE270025 | GEO
| PRJNA1106833 | ENA
2024-09-20 | PXD048276 | Pride
2024-06-10 | PXD052986 |
2020-09-02 | PXD020011 | Pride